by The global osteoporosis treatment market size was estimated to be around US$ 18.45 billion in 2022. It is projected to reach US$ 11.6 billion by 2032, indicating a CAGR of 4.8% from 2023 to 2032.
Key Takeaways
- North America led the global market with a major market share of 41% in 2022.
- Asia-Pacific is expected to expand at the fastest CAGR of 6.3% during the forecast period.
- By Drug Class, the prostacyclin and prostacyclin analogs segment contributed more than 45% of revenue share in 2022.
- By Drug Class, the hormone replacement therapy drugs segment is anticipated to grow at a CAGR of 5.1% during the projected period.
- By Route of Administration, the parenteral segment had the biggest market share of 65% in 2022.
- By Route of Administration, the oral segment is projected to expand at the fastest CAGE over the projected period.
- By Distribution Channel, the hospital pharmacies segment captured more than 44% of revenue share in 2022.
- By Distribution Channel, the other segment is expected to expand at the fastest CAGR over the projected period.
Osteoporosis Treatment Market Overview:
The Osteoporosis Treatment Market is a dynamic sector within the healthcare industry dedicated to addressing the challenges posed by osteoporosis, a condition characterized by weakened bones and an increased risk of fractures. The market encompasses a range of therapeutic approaches and pharmaceutical interventions aimed at preventing bone loss, promoting bone formation, and ultimately reducing the incidence of fractures in individuals affected by osteoporosis.
Get a Sample: https://www.precedenceresearch.com/sample/3419
Osteoporosis Treatment Market Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 12.10 Billion |
| Market Size by 2032 | USD 18.45 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 4.8% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Drug Class, By Route of Administration, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Radiopharmaceuticals Market Size to Garner USD 13.67 Billion by 2032
Growth Factors:
The growth of the Osteoporosis Treatment Market is fueled by several key factors. Firstly, the rising global aging population contributes significantly, as osteoporosis is more prevalent in older individuals. Additionally, increasing awareness about bone health and the proactive measures taken by healthcare organizations and professionals for early diagnosis and intervention drive market growth. Technological advancements in diagnostic tools and the development of innovative pharmaceuticals further enhance treatment options, catering to a broader spectrum of patients. Moreover, the growing emphasis on preventive healthcare and lifestyle modifications underscores the significance of the osteoporosis treatment market.
Regions Shanpshot:
The Osteoporosis Treatment Market exhibits a global presence, with regional variations influenced by demographic trends, healthcare infrastructure, and awareness levels. North America and Europe are prominent regions, given their well-established healthcare systems and a higher prevalence of osteoporosis in aging populations.
The Asia-Pacific region is witnessing substantial growth due to increasing healthcare investments, rising awareness, and a surge in the aging population. Latin America and the Middle East also contribute to the market expansion, albeit at a comparatively slower pace. As a truly global concern, the Osteoporosis Treatment Market reflects the collaborative efforts of healthcare professionals and industries across diverse regions.
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Recent Developments
- In August 2019, GEDEON Richter introduced the biosimilar teriparatide, known as Terrosa, into the European market following the expiration of its reference product’s patent. This product is designed for the treatment of osteoporosis in postmenopausal women and men with a high fracture risk, as well as for osteoporosis associated with prolonged systemic glucocorticoid therapy in women and men at an elevated risk of fractures.
- In January 2016, Taisho Pharmaceutical Co., Ltd. unveiled LOQOA tape, a novel anti-inflammatory analgesic patch formulation. This tape offers robust anti-inflammatory and analgesic properties, addressing the pain and inflammation associated with osteoarthritis.
Osteoporosis Treatment Market Key Players
- Amgen Inc.
- Eli Lilly and Company
- Novartis International AG
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- GlaxoSmithKline PLC
- Sanofi
- Johnson & Johnson
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Sun Pharmaceutical Industries Ltd.
- Mylan N.V.
Market Segmentations
By Drug Class
- Bisphosphonate
- Hormone Replacement Therapy
- Selective Estrogen Receptor Modulator (SERMs)
- RANK ligand (RANKL) Inhibitor
- Others
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Osteoporosis Treatment Market
5.1. COVID-19 Landscape: Osteoporosis Treatment Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Osteoporosis Treatment Market, By Drug Class
8.1. Osteoporosis Treatment Market, by Drug Class, 2023-2032
8.1.1 Bisphosphonate
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Hormone Replacement Therapy
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Selective Estrogen Receptor Modulator (SERMs)
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. RANK ligand (RANKL) Inhibitor
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Osteoporosis Treatment Market, By Route of Administration
9.1. Osteoporosis Treatment Market, by Route of Administration, 2023-2032
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Parenteral
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Osteoporosis Treatment Market, By Distribution Channel
10.1. Osteoporosis Treatment Market, by Distribution Channel, 2023-2032
10.1.1. Hospitals Pharmacies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Retail Pharmacies & Stores
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Osteoporosis Treatment Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 12. Company Profiles
12.1. Amgen Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Eli Lilly and Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis International AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Gilead Sciences, Inc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Merck & Co., Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. F. Hoffmann-La Roche Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Teva Pharmaceutical Industries Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Pfizer Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. GlaxoSmithKline PLC
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Sanofi
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
